92 related articles for article (PubMed ID: 8086615)
1. A Markov model for sequences of ordinal data from a relapsing-remitting disease.
Albert PS
Biometrics; 1994 Mar; 50(1):51-60. PubMed ID: 8086615
[TBL] [Abstract][Full Text] [Related]
2. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.
Humle Jorgensen S; Sorensen PS
J Neurol Sci; 2005 Jun; 233(1-2):61-5. PubMed ID: 15949496
[TBL] [Abstract][Full Text] [Related]
4. Experimental allergic encephalomyelitis as a guide to the understanding and treatment of multiple sclerosis.
Whitaker JN; Mitchell GW
Ann Neurol; 1993 Nov; 34(5):636-7. PubMed ID: 8239557
[No Abstract] [Full Text] [Related]
5. Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis.
Kobelt G; Jönsson L; Fredrikson S
Eur J Health Econ; 2003; 4(1):50-9. PubMed ID: 15609169
[TBL] [Abstract][Full Text] [Related]
6. Modeling disease-state transition heterogeneity through Bayesian variable selection.
Healy BC; Engler D
Stat Med; 2009 Apr; 28(9):1353-68. PubMed ID: 19206077
[TBL] [Abstract][Full Text] [Related]
7. Estimating disease progression using panel data.
Mandel M
Biostatistics; 2010 Apr; 11(2):304-16. PubMed ID: 20064845
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis.
Begolka WS; Vanderlugt CL; Rahbe SM; Miller SD
J Immunol; 1998 Oct; 161(8):4437-46. PubMed ID: 9780223
[TBL] [Abstract][Full Text] [Related]
9. Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE.
Skundric DS; Dai R; Zakarian VL; Bessert D; Skoff RP; Cruikshank WW; Kurjakovic Z
J Neurosci Res; 2005 Mar; 79(5):680-93. PubMed ID: 15682385
[TBL] [Abstract][Full Text] [Related]
10. Genetic analysis of disease subtypes and sexual dimorphisms in mouse experimental allergic encephalomyelitis (EAE): relapsing/remitting and monophasic remitting/nonrelapsing EAE are immunogenetically distinct.
Butterfield RJ; Blankenhorn EP; Roper RJ; Zachary JF; Doerge RW; Sudweeks J; Rose J; Teuscher C
J Immunol; 1999 Mar; 162(5):3096-102. PubMed ID: 10072563
[TBL] [Abstract][Full Text] [Related]
11. Chronic relapsing experimental allergic encephalomyelitis: an experimental model of multiple sclerosis.
Wiśniewski HM; Keith AB
Ann Neurol; 1977 Feb; 1(2):144-8. PubMed ID: 889297
[No Abstract] [Full Text] [Related]
12. Therapeutic activity of malononitrilamides (MNA 279 and MNA 715) on acute and chronic, relapsing, experimental, allergic encephalomyelitis (EAE).
Schorlemmer HU; Bartlett RR
Drugs Exp Clin Res; 1997; 23(5-6):175-81. PubMed ID: 9515227
[TBL] [Abstract][Full Text] [Related]
13. [Experimental allergic encephalomyelitis as an animal model for multiple sclerosis].
Lukinović-Skudar V; Taradi SK; Andreis I; Zupancić V; Taradi M
Lijec Vjesn; 2001; 123(3-4):81-8. PubMed ID: 11488222
[TBL] [Abstract][Full Text] [Related]
14. Effect of hematopoietic growth factors on severity of experimental autoimmune encephalomyelitis.
Verda L; Luo K; Kim DA; Bronesky D; Kohm AP; Miller SD; Statkute L; Oyama Y; Burt RK
Bone Marrow Transplant; 2006 Sep; 38(6):453-60. PubMed ID: 16951693
[TBL] [Abstract][Full Text] [Related]
15. A pathogenic role for gamma delta T cells in relapsing-remitting experimental allergic encephalomyelitis in the SJL mouse.
Rajan AJ; Gao YL; Raine CS; Brosnan CF
J Immunol; 1996 Jul; 157(2):941-9. PubMed ID: 8752949
[TBL] [Abstract][Full Text] [Related]
16. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
[TBL] [Abstract][Full Text] [Related]
17. Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein.
Meyer AL; Benson JM; Gienapp IE; Cox KL; Whitacre CC
J Immunol; 1996 Nov; 157(9):4230-8. PubMed ID: 8892661
[TBL] [Abstract][Full Text] [Related]
18. Exacerbation of protracted-relapsing experimental allergic encephalomyelitis in DA rats by gluten-free diet.
Di Marco R; Mangano K; Quattrocchi C; Amato F; Nicoletti F; Buschard K
APMIS; 2004 Oct; 112(10):651-5. PubMed ID: 15601316
[TBL] [Abstract][Full Text] [Related]
19. Chronic relapsing experimental allergic encephalomyelitis: cyclosporin-A treatment of relapsing and remitting disease.
Suckling AJ; Baron PW; Reiber H
J Clin Lab Immunol; 1986 Dec; 21(4):173-6. PubMed ID: 3560195
[TBL] [Abstract][Full Text] [Related]
20. Relapsing and remitting experimental autoimmune encephalomyelitis in B cell deficient mice.
Dittel BN; Urbania TH; Janeway CA
J Autoimmun; 2000 Jun; 14(4):311-8. PubMed ID: 10882057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
